What if the miracle molecule that changed obesity treatment isn’t the final answer? For years, therapeutic options were limited, while investments were modest. But thanks to the Glucagon-like peptide 1 (GLP-1) receptor antagonist, which gave birth to Semaglutide (Ozempic and Wegovy) and Tirzepatide (Zepbound), a paradigm shift in obesity treatment is taking on a new










